Development and optimization of a sublingual tablet formulation for physostigmine salicylate

Acta Pharmaceutica

Volumn 59, Issue 3, 2009, Pages 301-312

  Bolourchian, Noushin ^a   Hadidi, Naghmeh ^a   Foroutan, Seyed Mohsen ^a   Shafaghi, Bijan ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

D optimal mixture design; Physostigmine salicylate; Stability studies; Sublingual tablet

Indexed keywords

LACTOSE; NERVE GAS; PHYSOSTIGMINE SALICYLATE; POVIDONE; STARCH; STARCH GLYCOLATE SODIUM;

ALZHEIMER DISEASE; ARTICLE; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; HARDNESS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NEUROTOXICITY; PHYSICAL PARAMETERS; TABLET FORMULATION;

EID: 70350121642     PISSN: 13300075     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10007-009-0028-5     Document Type: Article

References (20)

1. Martindale, The Complete Drug Reference, 35th ed., Pharmaceutical Press, London 2007, p. 1723.
2. M. N. Madhat, Buccal and Sublingual Administration of Physostigmine, U.S. Pat. 6,264,974, 24 Jul 2001.
3. R. Whelpton and P. Hurst, Bioavailability of oral physostigmine, New Eng. J. Med. 313 (1985) 1293-1294.
4. D. Harris and J. R. Robinson, Drug delivery via the mucous membranes of the oral cavity, J. Pharm. Sci. 81 (1992) 1-10; DOI: 10.1002/jps.2600810102.
5. P. Mura, S. Furlanetto, M. Cirri, F. Maestrelli, A. M. Marras and S. Pinzauti, Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and D-optimal mixture experimental design, J. Pharm. Biomed. Anal. 37 (2005) 65-71.
6. R. C. Hwang and D. L. Kowalski, Design of experiments for formulation development, Pharm Tech Dec 1, 2005.
7. Introduction to Experimental Design, in Pharmaceutical Experimental Design and Interpretation, 2nd ed., N. A. Armstrong (Ed.), Taylor & Francis, London 2006, pp. 1-8.
8. X. Jin, Y. Zhang, L. Xiao and Z. Zhao, Optimization of extended zero-order release gliclazide tablets using D-optimal mixture design, J. Pharm. Soc. Japan 128 (2008) 1475-1483.
9. Y. El-Malah, S. Nazzal and N. M. Khanfar, D-optimal mixture design: optimization of ternary matrix blends for controlled zero-order drug release from oral dosage forms, Drug Dev. Ind. Pharm. 32 (2006) 1207-1218; DOI: 10.1080/03639040600685167. (Pubitemid 44721735)
10. S. S. Patel, S. Ray and R. S. Thakur, Formulation and evaluation of floating drug delivery system containing clarithromycin for Helicobacter pylori, Acta Pol. Pharm. 63 (2006) 53-61.
11. Y. Gonnissen, S. I. Gonçalves, J. P. Remon and C. Vervaet, Mixture design applied to optimize a directly compressible powder produced via cospray drying, Drug Dev. Ind. Pharm. 34 (2008) 248-257; DOI: 10.1080/03639040701542143.
12. T. Nahata and T. R. Saini, D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole, Drug Dev. Ind. Pharm. 34 (2008) 668-675; DOI: 10.1080/ 03639040701836545.
13. A. Bodea and S. E. Leucuta, Optimization of hydrophilic matrix tablets using a D-optimal design, Int. J. Pharm. 153 (1997) 247-255; DOI: 10.1016/S0378-5173(97)00117-8. (Pubitemid 27308668)
14. R. C. Rowe, P. J. Sheskey and P. J. Weller, Handbook of Pharmaceutical Excipients, 5th ed., Pharmaceutical Press and American Pharmaceutical Association, London 2006.
15. United States Pharmacopeia 31, National Formulary 26, The United States Pharmacopeial Convention, Rockville 2008.
16. S. J. Ugarkovic, Sublingual Oral Dosage Form, U.S. Pat. 6,572,891, 3 Jun 2003.
17. G. Derringer and R. Suich, Simultaneous optimization of several response variables, J. Qual. Tech. 12 (1980) 214-219.
18. H. L. Fung, S. K. Yap and C. T. Rhodes, Development of a stable sublingual nitroglycerin tablet II: formulation and evaluation of tablets containing povidone, J. Pharm. Sci. 65 (1976) 558-560; DOI: 10.1002/jps. 2600650419.
19. C. P. Lim, S. S. Quek and K. K. Peh, Prediction of drug release profiles using an intelligent learning system: an experimental study in transdermal iontophoresis, J. Pharm. Biomed. Anal. 31 (2003) 159-168; DOI: 10.1016/S0731-7085(02)00573-3. (Pubitemid 36120630)
20. J. Klancke, Dissolution testing of orally disintegrating tablets, Diss. Tech. 10 (2003) 6-8.